drugset / Trial / NCT04086719

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

NCT04086719

Phase 1 Completed 16 enrolled Bristol-Myers Squibb
Non-randomizedCrossoverOpen-labelTreatment

Summary

Study of what the body does to drug BMS-986165 when it is taken together with pyrimethamine

Timeline

Start
2019-09-12
Primary completion
2019-10-29
Completion
2019-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule Oral
Subject pyrimethamine Small molecule Oral

Indications

No indication recorded.